These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24828456)

  • 1. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model.
    Riviere MK; Yuan Y; Dubois F; Zohar S
    Pharm Stat; 2014; 13(4):247-57. PubMed ID: 24828456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
    Guo B; Li Y
    BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction.
    Pan H; Cheng C; Yuan Y
    Pharm Stat; 2020 Sep; 19(5):561-582. PubMed ID: 32248647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian optimal interval design for dose finding in drug-combination trials.
    Lin R; Yin G
    Stat Methods Med Res; 2017 Oct; 26(5):2155-2167. PubMed ID: 26178591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy.
    Yeung WY; Reigner B; Beyer U; Diack C; Sabanés Bové D; Palermo G; Jaki T
    Pharm Stat; 2017 Nov; 16(6):396-413. PubMed ID: 28691311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial design for drug combinations with Bayesian model averaging.
    Jin IH; Huo L; Yin G; Yuan Y
    Pharm Stat; 2015; 14(2):108-19. PubMed ID: 25641851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
    Koopmeiners JS; Modiano J
    Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose.
    Qiu Y; Zhao Y; Liu H; Cao S; Zhang C; Zang Y
    Contemp Clin Trials; 2023 Apr; 127():107139. PubMed ID: 36870476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approximate Bayesian computation design for phase I clinical trials.
    Jin H; Du W; Yin G
    Stat Methods Med Res; 2022 Dec; 31(12):2310-2322. PubMed ID: 36031856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple Bayesian decision-theoretic design for dose-finding trials.
    Fan SK; Lu Y; Wang YG
    Stat Med; 2012 Dec; 31(28):3719-30. PubMed ID: 22763943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic ordering design for dose finding in drug-combination trials.
    Zhang T; Yang Z; Yin G
    Pharm Stat; 2021 Mar; 20(2):348-361. PubMed ID: 33236520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.
    Takahashi A; Suzuki T
    Int J Biostat; 2021 Apr; 18(1):39-56. PubMed ID: 33818029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
    Liu R; Lin J; Li P
    Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible use of copula-type model for dose-finding in drug combination clinical trials.
    Hashizume K; Tshuchida J; Sozu T
    Biometrics; 2022 Dec; 78(4):1651-1661. PubMed ID: 34181760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian hybrid dose-finding design in phase I oncology clinical trials.
    Yuan Y; Yin G
    Stat Med; 2011 Jul; 30(17):2098-108. PubMed ID: 21365672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the relative conservativeness of Bayesian logistic regression method in oncology dose-finding studies.
    Yang CH; Cheng G; Lin R
    Pharm Stat; 2024; 23(4):585-594. PubMed ID: 38317370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
    Lin R; Yin G
    Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.